Clinical Trials Logo

Clinical Trial Summary

In COVID-19 deep airway and alveolar destruction occurred due to inflammatory reaction resulting into severe pneumonia. In COVID-19, lung injury is not only due to viral damage to tissue, but it is also due to immune response that leads to activation of inflammatory cells and release of cytokines. In COVID-19 acute respiratory distress syndrome ARDS is produced due to mucinous or cellular fibromyxoid exudates, desquamation of pneumocytes and alveolar damage and hyaline membrane development and within 5-7 days disease become more aggressive due to pneumonia and respiratory failure. It is important to start the prompt and strengthen treatment for suppression of inflammatory response and cytokine storm. Methylprednisolone are the traditional immunosuppressive drugs. They are important and effective to delay the pneumonia progression and treating the ARDS. Corticosteroids are broadly used as treatment for ARDS and there was an evidence for its efficacy for treating SARS and decreasing mortality of SARS in the past. However for COVID-19 corticosteroids efficacy and safety usage is still under clinical trials


Clinical Trial Description

All new decision and new interventions that are made for decreasing dependency of ventilator in patients and decreasing patients mortality would have played a great role on global public health. The aim of the study is to address the efficacy of methlyprednisolone for the treatment of COVID-19 patients and its clinical outcome at a tertriary care hospital. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04559113
Study type Interventional
Source Lahore General Hospital
Contact Muhammad Irfan Malik, FCPS
Phone 03334367220
Email drmirfanmalik@hotmail.com
Status Recruiting
Phase N/A
Start date May 1, 2020
Completion date December 30, 2020

See also
  Status Clinical Trial Phase
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546776 - COVID-19 Persistence in Stool
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT05065827 - Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
Completed NCT04542915 - COVID-19-Related Health and Practices Among Dental Hygienists
Recruiting NCT04615052 - Home-based Exercise in COVID-19 Survivors N/A
Enrolling by invitation NCT04659486 - Adolescents With COVID-19/MIS-C at HCFMUSP N/A
Recruiting NCT04885452 - Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') OR or Authorisation for Early Access (AAP). A Prospectvie Cohort.
Active, not recruiting NCT05063812 - Performance of a Remote Monitoring Program for Patients Diagnosed With COVID-19
Completed NCT04516928 - Study of SARS-CoV2 Virus (COVID-19) Seroprevalence Among Lyon-Bron Military Health Schools Personnel
Completed NCT04530357 - Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine Phase 1/Phase 2
Recruiting NCT04565782 - Corona Virus Infection Among Liver Transplant Recipients
Completed NCT04550390 - Study of the Analytical Performance of Different Salivary Self-collection Methods for the Detection of COVID-19
Completed NCT04733625 - The Effect of Vitamin D Therapy on Morbidity and Moratlity in Patients With SARS-CoV 2 Infection N/A
Active, not recruiting NCT04517136 - Impact of Perceived Control on Operational Strain: a Study of COVID-19 Pandemic Caregivers and Military Personnel on Operational Missions
Not yet recruiting NCT05886816 - Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19 Phase 2
Recruiting NCT04476680 - Influence of Military Preventive Policy for reCruit Training on COVID-19 Seroconversion N/A
Completed NCT04839913 - Seroprevalence of SARS-CoV-2 in Unselected Surgical Patients: an Unicentric, Regional Study
Completed NCT04514874 - Assessment of the Prevalence and the Impact of the COVID-19 Epidemic in the French Flight Crew in 2020
Terminated NCT04606563 - Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? Phase 3